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Menopause 
Daniel R. Mishell Jr, MD 
The decline of ovarian function occurs gradually, and the 
cessation of menses is only one facet of the climacteric process. 
After the menopause, ovarian production of estrogen ceases and 
circulating levels fall dramatically. 
Decreasing estrogen production leads to atrophy of the vagina, 
which can produce the distressful symptom of senile vaginitis or 
atrophic vaginitis. Estrogen deprivation also can cause the 
structures that support the uterus, the cardinal and uterosacral 
ligaments, to lose their tonicity and uterine descensus could 
occur. The trigone of the bladder and the urethra are embryologi-
cally derived from estrogen-dependent tissue, and estrogen 
deficiency can lead to their atrophy, producing symptoms of 
urinary urgency incontinence, dysuria, and urinary frequency. 
Another problem that can develop with decreased circulating 
estrogen levels is decreased synthesis of collagen that forms the 
connective tissue beneath the vaginal/epithelium. This change 
may decrease the support of the posterior urethro-vesicle angle 
and urinary stress incontinence can develop. Loss of collagen 
also can lead to clinically symptomatic cystoceles and/or 
rectoceles. These urinary symptoms can be alleviated or pre-
vented with estrogen replacement therapy. 
The pathognomonic symptom of menopause is the hot flush or 
flash, which is caused by a decrease in circulating estrogen 
levels. About 75% of all women going through menopause 
develop hot flushes. These flushes frequently occur at night, 
awaken the individual, and then produce insomnia. Hot flushes 
do not persist in most women for more than 2 to 3 years, and it 
is uncommon for a woman to have hot flushes that last more than 
5 years after menopause. The most effective treatment for the hot 
flush is estrogen. Since so many of the hot flushes occur at night, 
it is advisable for the patient to ingest the estrogen tablet before 
bedtime. 
Several studies have demonstrated that estrogen improves 
many psychological symptoms significantly better than pla-
cebo, particularly depression, in addition to relieving the hot 
flush and allowing the patient to sleep better. Estrogen users are 
less likely to develop dementia and Alzheimer's disease than 
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non-estrogen users. Postmenopausal estrogen users have sig-
nificantly thicker skin and a greater amount of collagen in the 
dermis than non-estrogen users. Systemic estrogen use can 
retard wrinkling and thinning of the skin postmenopausally. 
Osteoporosis is defmed as an asymptomatic reduction in the 
mass-per-unit bone volume (density) so that there is a signifi-
cantly increased risk of fracture in the absence of trauma. 
Postmenopausal osteoporosis initially affects trabecular bone 
that is present in the vertebral column and distal radius. 
Osteoporosis develops more slowly in cortical bone, which is 
present in the limbs. About 1% to 2% of bone mass is lost each 
year after menopause. Osteoporosis is an asymptomatic disease, 
and its presence usually is not detected until a fracture occurs 
many years later. At least 25% of the bone needs to be lost before 
osteoporosis is diagnosed by routine x-ray examination, so other 
procedures such at CT scan or DEXA are used to detect this 
disorder. 
In women undergoing a normal menopause, fractures begin to 
occur about age 60 in structures composed mainly of trabecular 
bone. By age 60,25% of Caucasian and Oriental women develop 
spinal compression fractures. Loss of bone mass in cortical bone 
occurs at a much slower rate, so osteoporotic fractures of the 
femur usually do not begin to occur until about age 70 or 75. 
Patients with osteoporosis have a higher bone resorption rate 
than normal. With a few months of estrogen treatment, bone 
resorption rates returned to normal. Bone formation in patients 
with osteoporosis is normal before and after the estrogen therapy. 
The best way to prevent loss of calcium from bone in postmeno-
pausal women is to administer exogenous estrogens. 
Epidemiologic studies have shown that estrogen therapy re-
duces the amount of postmenopausal bone loss as well as the 
incidence of fracture. The minimum dosage of estrogen needed 
to prevent osteoporosis is 0.625 mg of conjugated equine estro-
gens, 0.625 mg of estrone sulfate and 0.5 mg of micronized 
estradiol. Ingesting the recommended daily intake of dietary 
calcium (800 mg to 1000 mg/day) during the adolescent years 
results in greater peak adult bone mass than occurs if insufficient 
calcium is ingested. Thus, postmenopausally with steady loss of 
bone, women who when premenopausal ingested the recom-
mended intake of calcium are less likely to have sufficient 
reduction in bone density to cause fractures than those ingesting 
insufficient calcium. Dietary calciutn supplementation without 
estrogen or weight-bearing exercise do not prevent postmeno-
pausal bone loss. 
In contrast to the increase in blood pressure that has been 
reported in some women using oral contraceptives, no such 
increase has been observed with use of estrogen replacement 
therapy. It is safe to prescribe estrogen replacement for post-
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menopausal women with hypertension, and if blood pressure 
increases while they are receiving this treatment, it is unlikely 
that the estrogen is the cause of the blood pressure elevation. 
There is no epidemiologic evidence of an increased incidence of 
thrombophlebitis or thromboembolism in postmenopausal es-
trogen users as compared with control subjects. 
An abundance of epidemiologic data indicates that estrogen 
replacement therapy retards the development of atherosclerosis 
in postmenopausal women and reduces their risks of developing 
myocardial infarctions and cerebrovascular accident (CV A, 
stroke) by about 50%. The main mechanism whereby oral 
estrogen replacement retards atherosclerosis postmenopausally 
is prevention of the adverse alterations in endogenous circulat-
ing lipid levels that normally occur after the menopause, but 
estrogen also acts directly on the arterial system to improve 
blood flow. 
Much concern has been raised about the neoplastic risks of 
postmenopausal estrogen replacement therapy, particularly breast 
and endometrial cancer, since these areas are estrogen target 
tissues. 
The possibility exists that estrogen can stimulate anonpalpable 
breast cancer, and carcinoma of the breast can exist in the 
preclinical state for as long as 8 years before it is palpable. 
Therefore it is advisable to obtain a mammogram to rule out 
subclinical breast cancer on all patients before initiating estro-
gen therapy and annually thereafter. 
Many epidemiologic studies have investigated the relation of 
exogenous estrogen and the incidence of breast cancer. The 
epidemiologic data generally are reassuring as most studies 
show no increased risk of development of breast cancer among 
postmenopausal estrogen users, with the possibility of a slightly 
increased risk with long-term use. At present, it is not clear what 
effect if any the addition of a progestin to estrogen replacement 
therapy has on the risk of breast cancer. 
Many epidemiologic studies have reported there is signifi-
cantly increased risk of endometrial cancer developing in post-
menopausal women who are ingesting estrogen without 
progestins as compared with non-estrogen users. The risk ~­
creases with increasing duration of use of estrogen and wtth 
increasing dosage. The endometrial cancer that develops in 
estrogen users is nearly always well differentiated and is usually 
cured by performing a simple hysterectomy. The risk of devel-
oping endometrial carcinoma for women receiving estrogen 
replacement can be markedly reduced by giving progestogens. 
The use of progestins lowers the chances of postmenopausal 
estrogen users' developing cancer of the endometrium, and 
therefore progestins should usually be given to postmenopausal 
women receiving estrogen if they have a uterus. The addition of 
a progestin to estrogen therapy does not appear to cause an 
increase of any other systemic disease and acts synergistically 
with estrogen to cause a slight increase in bone density. The use 
of synthetic progestins, however, may reverse the beneficial 
effect of estrogen upon serum lipids. 
One of the primary reasons that postmenopausal women 
decide not to use estrogen, or discontinue its use, is the occur-
rence of uterine bleeding. For this reason, combination instead 
of sequential estrogen-progestin regimens are being increas-
-
ingly prescribed as the former regime is usually associated with 
no bleeding after the first few months. For women without a 
uterus it is unnecessary to add a progestin. 
Domestic Violence-A Medical Perspective 
>-(Continued from Page 243) 
4,000 women are killed in the U.S. each year by their current or 
former partners, with the great majority of these murders occur-
ring after the woman has ended the relationship. During the 
1980s alone, an estimated 50,000 American women died as a 
result of domestic violence. Incredibly, this figure nearly matches 
the number of U.S. fatalities for the Vietnam war. 
How are we as a society to respond to this new understanding 
of domestic violence as a medical crisis? One way to begin is by 
providing training for health care providers and insisting that 
medical schools include domestic violence education in their 
curriculums-medical providers have the potential to reach 
countless victims. Since almost all battered women must occa-
sionally see family doctors, pediatricians, dentists, counselors, 
or others in the health care field, opportunities abound to 
recognize the indicators of abuse and to make referrals to life-
saving resources. 
In order to heighten the awareness of the medical community, 
and society at large, however, we must begin as individuals to 
shed our own heavy denial, which protects us from facing the 
true enormity, severity, and randomness of domestic violence. 
We must shatter our outdated stereotypes about why abuse 
occurs once and for all, and exactly who "those people"-
victims and batterers-really are. In addition, we must stop 
blaming the victim by constantly asking, "Why does she stay?" 
and instead refocus our attention and indignation on the person 
using the violence by asking, "Why does he hit?" 
Corning to terms with any unpleasant social truth is an uncom-
fortable experience. To let go of denial and grasp, for perhaps the 
first time, the truly devastating ramifications of domestic vio-
lence is especially disturbing. There is no going back. But until 
we as individuals are willing to risk some degree of personal 
discomfort in exchange for the truth, we will be robbing our-
selves of golden opportunities to help many victims-perhaps 
even our own co-workers, neighbors, friends, sisters, daughters, 
or mothers-who may someday tell us that their injuries are 
from a "fall down the stairs" or from "playing volleyball." 
Editor's Note 
In 1989, after surviving a brutal attack in which she was beaten 
and stabbed by her estranged husband, Julie Owens left her 
career in special education and devotes her full-time efforts to 
the field of family violence. She gives domestic violence traini~g 
seminars to professionals and trains officers and counselors m 
the Honolulu Police Department's DART program (Domestic 
Abuse Response Team). 
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